These independent CME/CE activities are supported by educational grants from

AbbVie Inc.



Certificate Program Banner Goes Here
  1. Course List
CME/CE Information

Target Audience

The target audience for this activity series includes the care team that manages patients with chronic lymphocytic leukemia, including hematologists, oncologists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists.

Activity Goal

The goal of this program is to enhance the contemporary management of chronic lymphocytic leukemia and patient outcomes. Focusing on evolving concepts and addressing clinical challenges, the Master Class curriculum will include innovative webcasts derived from the latest evidence, interactive real-world cases, and faculty insights from recent peer-reviewed journal articles. The program is designed to provide scientific and practical knowledge that can be applied by practicing clinicians directly into their clinical practice.

Learning Objective (s)

  • Summarize the rationale for using minimal residual disease (MRD) as an endpoint and strategies for achieving MRD negativity
  • Implement personalized treatment strategies for patients with ibrutinib-refractory CLL using patient factors to guide selection
  • Describe supportive care, prophylaxis of TLS, and special considerations for the use of small-molecule inhibitors in the treatment of CLL


CME Information: Physicians


Statement of Accreditation

Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Projects In Knowledge® designates this enduring material for a maximum of 6.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Instructions


To obtain CME credit:

  1. Read or listen to each activity carefully.
  2. Complete/submit each posttest and evaluation.
  3. Instantly access and print out your certificate.

There is no fee for this activity.

CONTRACT FOR MUTUAL RESPONSIBILITY IN CME

Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here.
Disclosure Information

The Disclosure Policy of Projects In Knowledge® requires that all those who have control of content comply with the Standards for Commercial Support. Faculty, planners, PIK editorial scientific team, reviewers, and medical writers are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed during the presentations.

Bruce D. Cheson, MD, FACP, FAAAS has received consulting fees from AbbVie, Inc., Acerta Pharma, Celgene Corporation, Hoffman-La Roche Ltd/Genentech, and TG Therapeutics, Inc.

Anthony R. Mato, MD, MSCE

Susan M. O'Brien, MD, MA, BA has received consulting fees from AbbVie, Inc., Alexion Pharmaceuticals, Inc, Amgen Inc., Aptose Biosciences Inc., Astellas Pharma, Inc, Celgene, Gilead Sciences, Inc., GlaxoSmithKline, Janssen Oncology, Pfizer Inc, Pharmacyclics Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics, Inc., and Vanlam Group LLC; and has contracted research for Acerta Pharma, Gilead Sciences, Inc., Kite Pharma Inc., Pfizer Inc, Regeneron Pharmaceuticals, Pharmacyclics Inc, Sunesis Pharmaceuticals Inc, and TG Therapeutics, Inc.

Lindsey E. Roeker, MD, MSCE

William G. Wierda, MD, PhD has conducted contracted research for AbbVie, Inc., Acerta Pharma, Cyclacel Pharmaceuticals, Inc, Genentech, Gilead Sciences, Inc., GlaxoSmithKline/Novartis, Juno Therapeutics, Karyopharm Therapeutics, Kite Pharma Inc., miRagen Therapeutics, Inc, Oncternal Therapeutics, Pharmacyclics, Inc, and Sunesis Pharmaceuticals, Inc.

Peer Reviewer has disclosed no relevant relationships.

Projects In Knowledge's staff members have no relevant relationships to disclose.

These activities may contain discussions of unlabeled/unapproved uses of drugs or devices. Specific product disclosure will be forthcoming in each activity.

The opinions expressed in these activities are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

These independent CME/CE activities are supported by educational grants from AbbVie Inc.

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

2340